CL2021003536A1 - Hidrato cristalino 3 de 8-(2-fluorobencil)-6-(3-(trifluorometil)-1h-1,2,4-triazol-5-il)imidazo[1,2-a]pirazina . solicitud divisional de solicitud 2284-2020 - Google Patents

Hidrato cristalino 3 de 8-(2-fluorobencil)-6-(3-(trifluorometil)-1h-1,2,4-triazol-5-il)imidazo[1,2-a]pirazina . solicitud divisional de solicitud 2284-2020

Info

Publication number
CL2021003536A1
CL2021003536A1 CL2021003536A CL2021003536A CL2021003536A1 CL 2021003536 A1 CL2021003536 A1 CL 2021003536A1 CL 2021003536 A CL2021003536 A CL 2021003536A CL 2021003536 A CL2021003536 A CL 2021003536A CL 2021003536 A1 CL2021003536 A1 CL 2021003536A1
Authority
CL
Chile
Prior art keywords
application
crystalline hydrate
fluorobenzyl
imidazo
triazol
Prior art date
Application number
CL2021003536A
Other languages
English (en)
Inventor
Thomas Storz
Leena Kumari Prasad
Kwame W Nti-Addae
Original Assignee
Cyclerion Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cyclerion Therapeutics Inc filed Critical Cyclerion Therapeutics Inc
Publication of CL2021003536A1 publication Critical patent/CL2021003536A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente divulgación se relaciona con el hidrato cristalino 3 de 8-(2-fluorobencil)-6-(3-(trifluorometil)-1H-1,2,4-triazol-5-il)imidazo[1,2-a]pirazina, que son útiles como estimuladores de guanilato ciclasa soluble (sGC). La presente divulgación también provee composiciones farmacéuticamente aceptables que comprenden el hidrato cristalino 3 y métodos para usar dichas composiciones en el tratamiento de diversas afecciones.
CL2021003536A 2018-03-07 2021-12-28 Hidrato cristalino 3 de 8-(2-fluorobencil)-6-(3-(trifluorometil)-1h-1,2,4-triazol-5-il)imidazo[1,2-a]pirazina . solicitud divisional de solicitud 2284-2020 CL2021003536A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862639846P 2018-03-07 2018-03-07

Publications (1)

Publication Number Publication Date
CL2021003536A1 true CL2021003536A1 (es) 2022-08-19

Family

ID=65818696

Family Applications (5)

Application Number Title Priority Date Filing Date
CL2020002284A CL2020002284A1 (es) 2018-03-07 2020-09-03 Formas cristalinas de un estimulante de la guanilil ciclasa soluble (sgc)
CL2021000301A CL2021000301A1 (es) 2018-03-07 2021-02-04 Formas cristalinas de un estimulante de la guanilil ciclasa soluble (sgc). solicitud divisional de sol. 2284-2020.
CL2021003536A CL2021003536A1 (es) 2018-03-07 2021-12-28 Hidrato cristalino 3 de 8-(2-fluorobencil)-6-(3-(trifluorometil)-1h-1,2,4-triazol-5-il)imidazo[1,2-a]pirazina . solicitud divisional de solicitud 2284-2020
CL2021003530A CL2021003530A1 (es) 2018-03-07 2021-12-28 Hidrato cristalino 1 de 8-(2-fluorobencil)-6-(3-(trifluorometil)-1h-1,2,4-triazol-5-il)imidazo[1,2-a]pirazina solicitud divisional de solicitud 2284-2020.
CL2021003531A CL2021003531A1 (es) 2018-03-07 2021-12-28 Hidrato cristalino 2 de 8-(2-fluorobencil)-6-(3-(trifluorometil)-1h-1,2,4-triazol-5-il)imidazo[1,2-a]pirazina. solicitud divisional de solicitud 2284-2020

Family Applications Before (2)

Application Number Title Priority Date Filing Date
CL2020002284A CL2020002284A1 (es) 2018-03-07 2020-09-03 Formas cristalinas de un estimulante de la guanilil ciclasa soluble (sgc)
CL2021000301A CL2021000301A1 (es) 2018-03-07 2021-02-04 Formas cristalinas de un estimulante de la guanilil ciclasa soluble (sgc). solicitud divisional de sol. 2284-2020.

Family Applications After (2)

Application Number Title Priority Date Filing Date
CL2021003530A CL2021003530A1 (es) 2018-03-07 2021-12-28 Hidrato cristalino 1 de 8-(2-fluorobencil)-6-(3-(trifluorometil)-1h-1,2,4-triazol-5-il)imidazo[1,2-a]pirazina solicitud divisional de solicitud 2284-2020.
CL2021003531A CL2021003531A1 (es) 2018-03-07 2021-12-28 Hidrato cristalino 2 de 8-(2-fluorobencil)-6-(3-(trifluorometil)-1h-1,2,4-triazol-5-il)imidazo[1,2-a]pirazina. solicitud divisional de solicitud 2284-2020

Country Status (20)

Country Link
US (2) US11466015B2 (es)
EP (1) EP3762389B1 (es)
JP (1) JP7423539B2 (es)
KR (1) KR20200128708A (es)
CN (1) CN111836812A (es)
AU (1) AU2019231724B2 (es)
BR (1) BR112020018212A2 (es)
CA (1) CA3092683A1 (es)
CL (5) CL2020002284A1 (es)
CO (1) CO2020012493A2 (es)
CR (1) CR20200458A (es)
EA (1) EA202092109A1 (es)
IL (1) IL276853A (es)
MA (1) MA54638A (es)
MX (5) MX2023004858A (es)
PE (1) PE20210124A1 (es)
PH (1) PH12020551394A1 (es)
SG (1) SG11202008641WA (es)
TW (1) TWI823903B (es)
WO (1) WO2019173551A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202100092QA (en) * 2018-07-11 2021-02-25 Cyclerion Therapeutics Inc USE OF sGC STIMULATORS FOR THE TREATMENT OF MITOCHONRIAL DISORDERS
US20230130739A1 (en) * 2020-03-26 2023-04-27 Cyclerion Therapeutics, Inc. DEUTERATED sGC STIMULATORS

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2928079B2 (ja) 1994-02-14 1999-07-28 永信薬品工業股▲ふん▼有限公司 １−（置換ベンジル）−３−（置換アリール）縮合ピラゾール類、その製造法及びその用途
DE19744026A1 (de) 1997-10-06 1999-04-08 Hoechst Marion Roussel De Gmbh Pyrazol-Derivate, ihre Herstellung und ihre Verwendung in Arzneimitteln
DE19830430A1 (de) 1998-07-08 2000-01-13 Hoechst Marion Roussel De Gmbh Schwefelsubstituierte Sulfonylamino-carbonsäure-N-arylamide, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
KR100720844B1 (ko) 1998-07-08 2007-05-25 사노피-아벤티스 도이칠란트 게엠베하 황 치환된 설포닐아미노카복실산 ｎ-아릴아미드, 이의 제조방법, 및 이를 함유하는 약제학적 제제
DE19834044A1 (de) 1998-07-29 2000-02-03 Bayer Ag Neue substituierte Pyrazolderivate
DE19834047A1 (de) 1998-07-29 2000-02-03 Bayer Ag Substituierte Pyrazolderivate
GB9824310D0 (en) 1998-11-05 1998-12-30 Univ London Activators of soluble guanylate cyclase
DE19942809A1 (de) 1999-09-08 2001-03-15 Bayer Ag Verfahren zur Herstellung substituierter Pyrimidinderivate
DE19943635A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE10216145A1 (de) 2002-04-12 2003-10-23 Bayer Ag Verwendung von Stimulatoren der löslichen Guanylatcyclase zur Behandlung von Glaukom
DE10220570A1 (de) 2002-05-08 2003-11-20 Bayer Ag Carbamat-substituierte Pyrazolopyridine
EA201070339A1 (ru) 2007-09-06 2010-10-29 Мерк Шарп Энд Домэ Корп. Активаторы растворимой гуанилатциклазы
JP2011510082A (ja) 2008-01-24 2011-03-31 メルク・シャープ・エンド・ドーム・コーポレイション アンジオテンシンｉｉ受容体拮抗薬
CA2743864A1 (en) 2008-11-25 2010-06-10 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
CA2753434C (en) 2009-02-26 2014-07-15 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
EP2549875B1 (en) 2010-03-25 2015-05-13 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
MA34330B1 (fr) 2010-05-27 2013-06-01 Merck Sharp & Dohme Activateurs de guanylate cyclase soluble
US8895583B2 (en) 2010-10-28 2014-11-25 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
CN104327107A (zh) 2013-10-17 2015-02-04 广东东阳光药业有限公司 一种氟喹诺酮类抗菌药物的制备方法
EP3152214B1 (en) 2014-06-04 2020-01-29 Merck Sharp & Dohme Corp. Imidazo-pyrazine derivatives useful as soluble guanylate cyclase activators
CA2969265A1 (en) * 2014-12-02 2016-06-09 Bayer Pharma Aktiengesellschaft Substituted pyrazolo[1,5-a]pyridines and imidazo[1,2-a]pyrazines and their use
US10472363B2 (en) 2016-09-02 2019-11-12 Cyclerion Therapeutics, Inc. SGC stimulators

Also Published As

Publication number Publication date
PH12020551394A1 (en) 2021-11-22
MA54638A (fr) 2021-11-10
CL2021003531A1 (es) 2022-08-19
BR112020018212A2 (pt) 2020-12-29
WO2019173551A8 (en) 2020-06-11
CA3092683A1 (en) 2019-09-12
EP3762389B1 (en) 2024-02-28
JP7423539B2 (ja) 2024-01-29
CL2021003530A1 (es) 2022-08-19
US20210115050A1 (en) 2021-04-22
CO2020012493A2 (es) 2020-10-30
PE20210124A1 (es) 2021-01-19
CL2020002284A1 (es) 2020-11-27
US20230095799A1 (en) 2023-03-30
EA202092109A1 (ru) 2021-03-04
US11466015B2 (en) 2022-10-11
IL276853A (en) 2020-10-29
TW201940487A (zh) 2019-10-16
EP3762389A1 (en) 2021-01-13
CN111836812A (zh) 2020-10-27
AU2019231724B2 (en) 2024-06-27
MX2023004855A (es) 2023-11-24
JP2021515015A (ja) 2021-06-17
MX2023004858A (es) 2023-11-24
TWI823903B (zh) 2023-12-01
WO2019173551A1 (en) 2019-09-12
CR20200458A (es) 2020-11-09
SG11202008641WA (en) 2020-10-29
MX2023004856A (es) 2023-11-24
MX2023004857A (es) 2023-11-24
KR20200128708A (ko) 2020-11-16
CL2021000301A1 (es) 2021-06-18
AU2019231724A1 (en) 2020-10-08
MX2020009183A (es) 2020-10-08

Similar Documents

Publication Publication Date Title
CL2021003530A1 (es) Hidrato cristalino 1 de 8-(2-fluorobencil)-6-(3-(trifluorometil)-1h-1,2,4-triazol-5-il)imidazo[1,2-a]pirazina solicitud divisional de solicitud 2284-2020.
MX2019002313A (es) Estimuladores de guanilato ciclasa soluble (sgc) biciclicos fusionados.
AR113758A1 (es) Proceso para la preparación de 6-(2-hidroxi-2-metilpropoxi)-4-(6-(6-((6-metoxipiridin-3-il)metil)-3,6-diazabiciclo[3.1.1]heptan-3-il)piridin-3-il)pirazolo[1,5-a]piridina-3-carbonitrilo
JOP20200315A1 (ar) مركبات بورينون واستخدامها في معالجة السرطان
PE20120121A1 (es) Derivados de imidazopirazina como inhibidores de syk
NZ744349A (en) Pyrazolo[1,5-a]pyrazin-4-yl derivatives as jak-inhibitors
EA202090659A1 (ru) СОСТАВЫ, СОДЕРЖАЩИЕ 6-(2-ГИДРОКСИ-2-МЕТИЛПРОПОКСИ)-4-(6-(6-((6-МЕТОКСИПИРИДИН-3-ИЛ)МЕТИЛ)-3,6-ДИАЗАБИЦИКЛО[3.1.1]ГЕПТАН-3-ИЛ)ПИРИДИН-3-ИЛ)ПИРАЗОЛО[1,5-a]ПИРИДИН-3-КАРБОНИТРИЛ
TN2019000107A1 (en) Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors
PE20181802A1 (es) Derivados de 4-amino-2-(1h-pirazolo[3,4-b]piridin-3-il)-6-oxo-6,7-dihidro-5h-pirrolo[2,3-d]pirimidina y los respectivos (1h-indazol-3-il) derivados como moduladores cgmp para el tratamiento de enfermedades cardiovasculares
MX2007004264A (es) Uso de inhibidores de cinasas jun n-terminales para el tratamiento de retinopat??a glaucomatosa y enfermedades oculares.
PE20170403A1 (es) COMPUESTOS DE IMIDAZO[4,5-c]QUINOLIN-2-ONA Y SU USO PARA TRATAR CANCER
EA030735B9 (ru) ПРИМЕНЕНИЕ sGC СТИМУЛЯТОРОВ ДЛЯ ЛЕЧЕНИЯ СИСТЕМНОГО СКЛЕРОЗА (SSc)
NZ607904A (en) Substituted imidazopyridazines
EA201691862A3 (ru) Имидазотриазины и имидазопиримидины в качестве ингибиторов киназы
ZA201100526B (en) Triazolo [4,5-d]pyramidine derivatives and their use as purine receptor antagonists
PE20171104A1 (es) Pirazolpiridinaminas como inhibidores de mknk1 y mknk2
EA202190323A1 (ru) ИМИДАЗО[1,2-b]ПИРИДАЗИНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ Trk
PH12019501017A1 (en) Sgc stimulators
EA202190322A1 (ru) ИМИДАЗО[1,2-b]ПИРИДАЗИНОВЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ TRK
MX2022012523A (es) Formas cristalinas de (9r,13s)-13-{4-[5-cloro-2-(4-cloro-1h-1,2,3- triazol-1-il)fenil]-6-oxo-1,6-dihidropirimidin-1-il}-3-(difluorom etil)-9-metil-3,4,7,15-tetraazatriciclo[12.3.1.0 2,6]octadeca-1(18),2(6),4,14,16-pentaen-8-ona.
MX2021008645A (es) Forma cristalina de un inhibidor de cinasa ciclinodependiente (cdk).
MX2023008755A (es) Cristales de sal.
PE20020581A1 (es) Derivados de pirazolpiridinas sustituidos con piridimidina como estimuladores de la guanilato ciclasa
TN2010000390A1 (en) Imidazo[1,2-b]pyridazine derivatives for the treatment of c-met tyrosine kinase mediated disease